{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T05:33:04Z","timestamp":1773725584235,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1124\/dmd.111.039099","type":"journal-article","created":{"date-parts":[[2011,3,26]],"date-time":"2011-03-26T03:01:18Z","timestamp":1301108478000},"page":"1181-1187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ocular Pharmacokinetics of Mapracorat, a Novel, Selective Glucocorticoid Receptor Agonist, in Rabbits and Monkeys"],"prefix":"10.1016","volume":"39","author":[{"given":"Joel W.","family":"Proksch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezra R.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith W.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.111.039099_bib2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/IAE.0b013e3180323de7","article-title":"Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone","volume":"27","author":"Augustin","year":"2007","journal-title":"Retina"},{"key":"10.1124\/dmd.111.039099_bib3","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/bjo.2008.154906","article-title":"Penetration of topical and subconjunctival corticosteroids into human aqueous humour and its therapeutic significance","volume":"93","author":"Awan","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1124\/dmd.111.039099_bib4","first-page":"151","article-title":"Factors affecting the intraocular penetration of antibiotics. The influence of route, inflammation, animal species and tissue pigmentation","volume":"14","author":"Barza","year":"1978","journal-title":"Scand J Infect Dis Suppl"},{"key":"10.1124\/dmd.111.039099_bib5","first-page":"485","article-title":"Ocular allergy: diagnosis and treatment","volume":"18","author":"Butrus","year":"2005","journal-title":"Ophthalmol Clin North Am"},{"key":"10.1124\/dmd.111.039099_bib6","first-page":"1791","article-title":"Mapracorat, a novel selective glucocorticoid receptor agonist, inhibits hyperosmolar-induced cytokine release and MAPK pathways in human corneal epithelial cells","volume":"16","author":"Cavet","year":"2010","journal-title":"Mol Vis"},{"key":"10.1124\/dmd.111.039099_bib7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1442-9071.1998.tb01330.x","article-title":"Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up","volume":"26","author":"Challa","year":"1998","journal-title":"Aust N Z J Ophthalmol"},{"key":"10.1124\/dmd.111.039099_bib8","first-page":"1769","article-title":"Glucocorticoid induction of the glaucoma gene MYOC in human and monkey trabecular meshwork cells and tissues","volume":"42","author":"Clark","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/dmd.111.039099_bib9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00006982-200003000-00004","article-title":"Intravitreal triamcinolone acetonide in exudative age-related macular degeneration","volume":"20","author":"Danis","year":"2000","journal-title":"Retina"},{"key":"10.1124\/dmd.111.039099_bib10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.coph.2010.04.007","article-title":"Targeting inflammation using selective glucocorticoid receptor modulators","volume":"10","author":"De Bosscher","year":"2010","journal-title":"Curr Opin Pharmacol"},{"key":"10.1124\/dmd.111.039099_bib11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/ICO.0b013e31815873c7","article-title":"Effects of loteprednol\/tobramycin versus dexamethasone\/tobramycin on intraocular pressure in healthy volunteers","volume":"27","author":"Holland","year":"2008","journal-title":"Cornea"},{"key":"10.1124\/dmd.111.039099_bib12","series-title":"Guide for the Care and Use of Laboratory Animals","year":"1996"},{"key":"10.1124\/dmd.111.039099_bib13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1542-0124(12)70085-X","article-title":"Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye Workshop (2007)","volume":"5","year":"2007","journal-title":"Ocul Surf"},{"key":"10.1124\/dmd.111.039099_bib14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/jop.2006.0067","article-title":"The etiology of steroid cataract","volume":"23","author":"James","year":"2007","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1124\/dmd.111.039099_bib15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0002-9394(99)00034-3","article-title":"Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis","volume":"127","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"10.1124\/dmd.111.039099_bib16","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.ophtha.2006.01.061","article-title":"Fourth-generation fluoroquinolone penetration into the aqueous humor in humans","volume":"113","author":"McCulley","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1124\/dmd.111.039099_bib17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/00365510601034736","article-title":"Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects","volume":"67","author":"Nieminen","year":"2007","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1124\/dmd.111.039099_bib18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000055552","article-title":"The ocular pharmacokinetics of topical diclofenac is affected by ocular inflammation","volume":"31","author":"Palmero","year":"1999","journal-title":"Ophthalmic Res"},{"key":"10.1124\/dmd.111.039099_bib19","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1167\/iovs.09-4202","article-title":"Reduced myocilin expression in cultured monkey trabecular meshwork cells induced by a selective glucocorticoid receptor agonist: comparison with steroids","volume":"51","author":"Pfeffer","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/dmd.111.039099_bib20","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archopht.1996.01100140208016","article-title":"Corticosteroid therapy of eye disease. Fifty years later","volume":"114","author":"Raizman","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1124\/dmd.111.039099_bib21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.mce.2008.10.008","article-title":"Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interaction","volume":"299","author":"Ronacher","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1124\/dmd.111.039099_bib22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000310711","article-title":"The influence of dexamethasone 0.1% eye drops on plasma cortisol and ACTH concentrations after cataract surgery","volume":"210","author":"Roters","year":"1996","journal-title":"Ophthalmologica"},{"key":"10.1124\/dmd.111.039099_bib23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/jop.1990.6.243","article-title":"Review: Systemic absorption of topically applied ocular drugs in humans","volume":"6","author":"Salminen","year":"1990","journal-title":"J Ocul Pharmacol"},{"key":"10.1124\/dmd.111.039099_bib24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.mce.2007.05.014","article-title":"Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index","volume":"275","author":"Sch\u00e4cke","year":"2007","journal-title":"Mol Cell Endocrinol"},{"key":"10.1124\/dmd.111.039099_bib25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-7258(02)00297-8","article-title":"Mechanisms involved in the side effects of glucocorticoids","volume":"96","author":"Sch\u00e4cke","year":"2002","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.111.039099_bib26","first-page":"524","article-title":"Dissociated glucocorticoid receptor ligands","volume":"5","author":"Sch\u00e4cke","year":"2004","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1124\/dmd.111.039099_bib27","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1073\/pnas.0300372101","article-title":"Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects","volume":"101","author":"Sch\u00e4cke","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.111.039099_bib28","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1476-5381.2009.00238.x","article-title":"Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases","volume":"158","author":"Sch\u00e4cke","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.111.039099_bib29","doi-asserted-by":"crossref","first-page":"52487","DOI":"10.1155\/2007\/52487","article-title":"Pharmacotherapies for diabetic retinopathy: present and future","volume":"2007","author":"Schwartz","year":"2007","journal-title":"Exp Diabetes Res"},{"key":"10.1124\/dmd.111.039099_bib30","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1167\/iovs.10-5598","article-title":"In vivo ocular efficacy profile of mapracorat, a novel selective glucocorticoid receptor agonist, in rabbit models of ocular disease","volume":"52","author":"Shafiee","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/dmd.111.039099_bib31","first-page":"2606","article-title":"BOL-303242-X, a novel selective glucocorticoid receptor agonist, with full anti-inflammatory properties in human ocular cells","volume":"15","author":"Zhang","year":"2009","journal-title":"Mol Vis"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624058045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624058045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.111.039099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:43:11Z","timestamp":1739904191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624058045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0090955624058045"],"URL":"https:\/\/doi.org\/10.1124\/dmd.111.039099","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular Pharmacokinetics of Mapracorat, a Novel, Selective Glucocorticoid Receptor Agonist, in Rabbits and Monkeys","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.111.039099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2011 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}